Administration of ATIII by inhalation provides more efficient treatment of lung disorders such as lung inflammation and injury than intravenous administration

摘要

Disclosed is the use of antithrombin III as a sole ingredient in the manufacture of an inhalation medicament for treating acute lung injury in a patient in need thereof, particularly when the medicament is formulated to provide a does of about 25-125 U/kg of body weight.